BR0215192A - Matrizes de proteìna modificadas pelo fator de desenvolvimento para construção do tecido - Google Patents
Matrizes de proteìna modificadas pelo fator de desenvolvimento para construção do tecidoInfo
- Publication number
- BR0215192A BR0215192A BR0215192-8A BR0215192A BR0215192A BR 0215192 A BR0215192 A BR 0215192A BR 0215192 A BR0215192 A BR 0215192A BR 0215192 A BR0215192 A BR 0215192A
- Authority
- BR
- Brazil
- Prior art keywords
- matrix
- heparin
- drug
- protein
- regeneration
- Prior art date
Links
- 238000010276 construction Methods 0.000 title 1
- 102000035118 modified proteins Human genes 0.000 title 1
- 108091005573 modified proteins Proteins 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229920000669 heparin Polymers 0.000 abstract 3
- 229960002897 heparin Drugs 0.000 abstract 3
- 238000011069 regeneration method Methods 0.000 abstract 3
- 238000012377 drug delivery Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000008929 regeneration Effects 0.000 abstract 2
- 230000017423 tissue regeneration Effects 0.000 abstract 2
- 108010000196 Factor XIIIa Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000007838 tissue remodeling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"MATRIZES DE PROTEìNA MODIFICADAS PELO FATOR DE DESENVOLVIMENTO PARA CONSTRUçãO DO TECIDO". Proteínas são incorporadas em matrizes de proteína ou polissacarídeo para uso em reparo, regeneração e/ou remodelagem de tecido e /ou liberação de droga. As proteínas podem ser incorporadas para que elas sejam liberadas por degradação da matriz, por difusão e/ou ação enzimática. Como demonstrado pelos exemplos, um método é para ligar heparina à matriz por métodos ou covalentes ou não-covalentes, para formar uma matriz de heparina. A heparina, em seguida, liga não-covalentemente fatores de desenvolvimento de ligação de heparina à matriz de proteína. Alternativamente, uma proteína de fusão pode ser construída a qual contém uma região de reticulação, tal como um substrato de fator XIIIa e a seq³ência de proteína natural. A incorporação de ligações degradáveis entre a matriz e os fatores bioativos pode ser particularmente útil quando liberação de droga de longa duração é desejada, por exemplo, no caso de regeneração de nervo, onde é desejável variar a taxa de liberação de droga espacialmente como uma função de regeneração, por exemplo, ligeiramente próximo da interface de tecido vivo e mais lentamente afastado dentro da zona de lesão. Benefícios adicionais incluem a dose de droga total mais baixa no sistema de liberação, e ajuste espacial de liberação que permite uma porcentagem maior da droga a ser liberada no momento de maior atividade celular.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/024,918 US20020168718A1 (en) | 1997-04-03 | 2001-12-18 | Enzyme-mediated modification of fibrin for tissue engineering |
| PCT/EP2002/012458 WO2003040235A1 (en) | 2001-11-07 | 2002-11-07 | Synthetic matrix for controlled cell ingrowth and tissue regeneration |
| US10/323,046 US7601685B2 (en) | 1998-08-27 | 2002-12-17 | Growth factor modified protein matrices for tissue engineering |
| PCT/US2002/041114 WO2003052091A1 (en) | 2001-12-18 | 2002-12-18 | Growth factor modified protein matrices for tissue engineering |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0215192A true BR0215192A (pt) | 2005-04-26 |
| BRPI0215192B1 BRPI0215192B1 (pt) | 2016-03-22 |
| BRPI0215192B8 BRPI0215192B8 (pt) | 2021-07-27 |
Family
ID=27807134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0215192A BRPI0215192B8 (pt) | 2001-12-18 | 2002-12-18 | peptídeo de fusão, kit e matriz que compreendem o mesmo, e método para criar uma matriz |
Country Status (9)
| Country | Link |
|---|---|
| JP (2) | JP4560291B2 (pt) |
| AT (1) | ATE386545T1 (pt) |
| AU (2) | AU2002358272B2 (pt) |
| BR (1) | BRPI0215192B8 (pt) |
| CA (1) | CA2470419A1 (pt) |
| DE (1) | DE60225185T2 (pt) |
| ES (1) | ES2301697T3 (pt) |
| MX (1) | MXPA04006021A (pt) |
| WO (1) | WO2003052091A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
| WO2006064381A2 (en) * | 2004-12-10 | 2006-06-22 | Straumann Holding Ag | Protein formulation |
| EP1862170B1 (en) | 2004-12-10 | 2012-03-14 | Straumann Holding AG | Enamel formulation with amelogenin |
| SE0403014D0 (sv) | 2004-12-10 | 2004-12-10 | Straumann Holding Ag | New protein formulation |
| EP1828244A2 (en) * | 2004-12-22 | 2007-09-05 | Kuros Biosurgery AG | Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| BRPI0606409A2 (pt) | 2005-01-06 | 2009-06-23 | Kuros Biosurgery Ag | matrizes suplementadas para o reparo de fraturas ósseas |
| ES2675174T3 (es) | 2007-04-09 | 2018-07-09 | The Board Of Trustees Of The University Of Arkansas | Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea |
| EP2136850B1 (en) | 2007-04-13 | 2012-02-01 | Kuros Biosurgery AG | Polymeric tissue sealant |
| WO2009047361A2 (en) * | 2007-10-12 | 2009-04-16 | Kuros Biosurgery Ag | Injectable fibrin compositions for tissue augmentation comprising strontium salt |
| CA2721477A1 (en) | 2008-04-18 | 2009-12-03 | Kuros Biosurgery Ag | Dispensing device, kit containing the device, and method of operating the device |
| WO2011025957A2 (en) * | 2009-08-28 | 2011-03-03 | Ecole Polytechnique Federal De Lausanne | Tg-aprotinin fusion proteins and matrices thereof |
| KR101922741B1 (ko) * | 2011-02-03 | 2019-02-20 | 노스이스턴 유니버시티 | 생물학적 물질의 고도로 특이적인 포획 및 방출을 위한 방법 및 조성물 |
| WO2012123028A1 (en) | 2011-03-16 | 2012-09-20 | Kuros Biosurgery Ag | Pharmaceutical formulation for use in spinal fusion |
| WO2013120060A1 (en) | 2012-02-09 | 2013-08-15 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents by a collagen binding protein |
| EP3391899B1 (en) | 2011-12-14 | 2020-07-15 | The Board of Trustees of the University of Arkansas | Delivery of therapeutic agents by a collagen binding protein |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| US9421245B2 (en) * | 2012-06-25 | 2016-08-23 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| WO2017042301A1 (en) * | 2015-09-09 | 2017-03-16 | ETH Zürich | Injectable macroporous hydrogels |
| WO2018148573A1 (en) | 2017-02-10 | 2018-08-16 | The Board Of Trustees Of The University Of Arkansas | Collagen-binding agent compositions and methods of using the same |
| EP3536353A1 (en) | 2018-03-09 | 2019-09-11 | Kuros Biosurgery AG | Method and kits for producing a fibrin matrix |
| US12403179B2 (en) | 2021-02-18 | 2025-09-02 | The Board Of Trustees Of The University Of Arkansas | Release of growth factors at wound healing stages |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171670A (en) * | 1989-05-12 | 1992-12-15 | The General Hospital Corporation | Recombinant dna method for production of parathyroid hormone |
| US5589452A (en) * | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| JP2000500019A (ja) * | 1995-11-16 | 2000-01-11 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ストレプトアビジン融合タンパク質経由でのペプチドの生産方法 |
| WO1999031137A1 (en) * | 1997-12-18 | 1999-06-24 | Eli Lilly And Company | Crystalline teriparatide |
| CA2359318C (en) * | 1999-02-01 | 2009-06-30 | Universitat Zurich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
| JP2001190280A (ja) * | 1999-02-19 | 2001-07-17 | Terumo Corp | コラーゲン結合性生理活性ポリペプチド |
-
2002
- 2002-12-18 ES ES02792510T patent/ES2301697T3/es not_active Expired - Lifetime
- 2002-12-18 AU AU2002358272A patent/AU2002358272B2/en not_active Expired
- 2002-12-18 DE DE60225185T patent/DE60225185T2/de not_active Expired - Lifetime
- 2002-12-18 CA CA002470419A patent/CA2470419A1/en not_active Abandoned
- 2002-12-18 MX MXPA04006021A patent/MXPA04006021A/es active IP Right Grant
- 2002-12-18 WO PCT/US2002/041114 patent/WO2003052091A1/en not_active Ceased
- 2002-12-18 AT AT02792510T patent/ATE386545T1/de not_active IP Right Cessation
- 2002-12-18 JP JP2003552958A patent/JP4560291B2/ja not_active Expired - Lifetime
- 2002-12-18 BR BRPI0215192A patent/BRPI0215192B8/pt not_active IP Right Cessation
-
2009
- 2009-01-13 JP JP2009005240A patent/JP2009102383A/ja active Pending
- 2009-04-21 AU AU2009201588A patent/AU2009201588B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JP4560291B2 (ja) | 2010-10-13 |
| AU2002358272A1 (en) | 2003-06-30 |
| DE60225185T2 (de) | 2009-02-19 |
| JP2005517658A (ja) | 2005-06-16 |
| WO2003052091A8 (en) | 2003-08-07 |
| MXPA04006021A (es) | 2005-08-19 |
| ES2301697T3 (es) | 2008-07-01 |
| JP2009102383A (ja) | 2009-05-14 |
| AU2009201588A1 (en) | 2009-05-14 |
| DE60225185D1 (de) | 2008-04-03 |
| BRPI0215192B1 (pt) | 2016-03-22 |
| AU2009201588B2 (en) | 2011-02-24 |
| CA2470419A1 (en) | 2003-06-26 |
| WO2003052091A1 (en) | 2003-06-26 |
| BRPI0215192B8 (pt) | 2021-07-27 |
| ATE386545T1 (de) | 2008-03-15 |
| AU2002358272B2 (en) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE386545T1 (de) | Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering) | |
| Kim et al. | Shear-induced alignment of collagen fibrils using 3D cell printing for corneal stroma tissue engineering | |
| DE60042795D1 (de) | Matrizen aus modifizierten wachstumfaktoren zum gewebeaufbau | |
| Hao et al. | Collagen/heparin bi‐affinity multilayer modified collagen scaffolds for controlled bFGF release to improve angiogenesis in vivo | |
| Seliktar | Extracellular stimulation in tissue engineering | |
| Lin et al. | Thiol–norbornene photoclick hydrogels for tissue engineering applications | |
| Tsuji et al. | BMP4 is dispensable for skeletogenesis and fracture-healing in the limb | |
| Nillesen et al. | Increased angiogenesis and blood vessel maturation in acellular collagen–heparin scaffolds containing both FGF2 and VEGF | |
| Holloway et al. | Synergistic effects of sdf‐1α and BMP‐2 delivery from proteolytically degradable hyaluronic acid hydrogels for bone repair | |
| Place et al. | Strontium-and zinc-alginate hydrogels for bone tissue engineering | |
| Gelberman et al. | The early effects of sustained platelet-derived growth factor administration on the functional and structural properties of repaired intrasynovial flexor tendons: an in vivo biomechanic study at 3 weeks in canines | |
| Ramburrun et al. | A review of bioactive release from nerve conduits as a neurotherapeutic strategy for neuronal growth in peripheral nerve injury | |
| WO2010060104A3 (en) | Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration | |
| BRPI0613401B8 (pt) | composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior | |
| Sun et al. | Crosslinking heparin to collagen scaffolds for the delivery of human platelet‐derived growth factor | |
| PT2239273E (pt) | Uma composição farmacêutica que compreende um fragmento fc de imunoglobulina como um portador | |
| BR112021019520A2 (pt) | Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica | |
| BR112014026088A2 (pt) | produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos | |
| Draenert et al. | BMP‐2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials | |
| BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
| Chen et al. | The fabrication of double-layered chitosan/gelatin/genipin nanosphere coating for sequential and controlled release of therapeutic proteins | |
| US20180140742A1 (en) | Graft material for nerve regeneration, method for producing graft material for nerve regeneration, and kit for producing graft material for nerve regeneration | |
| Song et al. | Sustained delivery of biomolecules from gelatin carriers for applications in bone regeneration | |
| AR046282A1 (es) | Biomateriales compuestos para implantes oseos | |
| Buckley et al. | Hyaluronic acid hybrid formulations optimised for 3D printing of nerve conduits and the delivery of the novel neurotrophic-like compound tyrosol to enhance peripheral nerve regeneration via Schwann cell proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 9/10 Ipc: A61K 38/29 (2006.01), A61K 33/06 (2006.01), C07K 1 |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/03/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2002, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 18/12/2022 |